Last reviewed · How we verify
Moderate-Dose Cannabidiol
Cannabidiol modulates endocannabinoid signaling and multiple receptor pathways to produce anti-inflammatory, anxiolytic, and neuroprotective effects.
Cannabidiol modulates endocannabinoid signaling and multiple receptor pathways to produce anti-inflammatory, anxiolytic, and neuroprotective effects. Used for Seizure disorders (epilepsy), Anxiety disorders, Chronic pain.
At a glance
| Generic name | Moderate-Dose Cannabidiol |
|---|---|
| Also known as | EPIDIOLEX® |
| Sponsor | Wayne State University |
| Drug class | Cannabinoid |
| Target | CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry, Immunology |
| Phase | Phase 3 |
Mechanism of action
Cannabidiol (CBD) is a non-intoxicating cannabinoid that acts as a negative allosteric modulator of CB1 and CB2 receptors, while also interacting with serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and other targets. These interactions produce anti-inflammatory, anticonvulsant, and anxiolytic effects without the psychoactive properties of THC. The moderate-dose formulation is designed to optimize therapeutic efficacy while minimizing adverse effects.
Approved indications
- Seizure disorders (epilepsy)
- Anxiety disorders
- Chronic pain
- Inflammation-related conditions
Common side effects
- Fatigue
- Diarrhea
- Changes in appetite
- Hepatic enzyme elevation
- Drug-drug interactions via CYP3A4/CYP2C19
Key clinical trials
- Unique Treatment of Oncology Pain in Advanced Cancer (PHASE2)
- Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder (PHASE3)
- Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial (PHASE2)
- Reducing Pain and Opioid Use With CBD (PHASE2)
- Cannabidiol After Multi-Trauma for Pain and Opioid Therapy (PHASE2)
- CBD for the Treatment of Alcohol Use Disorder (PHASE2)
- CBD for Individuals at Risk for Alzheimer's Disease (PHASE2)
- Alcohol Use Disorder and Cannabidiol (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderate-Dose Cannabidiol CI brief — competitive landscape report
- Moderate-Dose Cannabidiol updates RSS · CI watch RSS
- Wayne State University portfolio CI